[Latest] Global Antibacterial Drugs Market Size/Share Worth USD 67.9 Billion by 2032 at a 5.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 25, 2023 17:00 ET
|
Custom Market Insights
Austin, TX, USA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Antibacterial Drugs Market Size, Trends and Insights By Drug Class...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
October 30, 2017 08:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities
October 24, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
October 04, 2017 13:13 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
September 25, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics to Participate in Two Upcoming Investor Conferences
September 22, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens
September 18, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe
June 01, 2017 14:42 ET
|
Melinta Therapeutics
New Haven, Conn, June 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five...
Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries
March 02, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...
Melinta Therapeutics Provides Baxdela NDA Update
February 27, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...